IRCT20171230038142N21 IRCT 2020-09-21 Esfahan University of Medical Sciences The effect of Memantine in migraine patients The effect of Memantine on migraine pain severity,mental health and quality of life in patients with migraine 2019-08-21 anticipated 84 Complete https://irct.ir/trial/50618 interventional Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Sampling is non-probabilistic and sequential. In this way, all patients who are eligible to enter the study, enter the study until the sample size is completed. Then, using SPSS computer software, they are randomly assigned to two groups of control and intervention. 3 Migraine. Intervention 1: Control group:In this group, there are 42 patients with migraine who use topiramate at a dose of 50 mg made by Sobhan Iranian Pharmaceutical Company. This drug is used daily for two months as a prophylaxis. Topiramate is used once a night in this study. Intervention 2: Intervention group: For the intervention group, memantine at a dose of 10 mg daily for two months is used as prophylaxis. Also, topiramate at a dose of 50 mg daily for two months is used as prophylaxis. Topiramate was used once a night in this study, but the patient is responsible for the time of taking memantine and the specific time of day and night has no effect on its effect. Yes - There is a plan to make this available What will be shared: All data are available two years after the results are published after the patients are anonymous. When: Two years after the results are published To whom: Physicians and neurologists Conditions: Compare new drug or new dose with existing information Where to obtain: Send email to Fkhorvash@gmail.com How to obtain: Send email to Fkhorvash@gmail.com Comments: